[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial. [PDF]
Ferone D +22 more
europepmc +1 more source
Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy. [PDF]
Abdellatif AAH +11 more
europepmc +1 more source
Chronic Chylothorax in Childhood: Clinical Complexity and Management Challenges-A Case Report and Literature Overview. [PDF]
Bizerea-Moga TO +4 more
europepmc +1 more source
What is the future of acromegaly therapy?
Schilbach K, Strasburger CJ.
europepmc +1 more source
Controversies in NEN: An ENETS position statement on the interchangeability of somatostatin receptor PET tracers. [PDF]
Deroose CM +8 more
europepmc +1 more source
Optimising Non-operative Management of Inoperable Malignant Bowel Obstruction: A Clinical Review for Surgical Practice. [PDF]
Alkashty M, Kahka E, Hameed W, Eshra Y.
europepmc +1 more source
Current treatment landscape of acromegaly.
Castinetti F, Ioachimescu AG.
europepmc +1 more source
Adenoma receptors and histologic characteristics determining management outcomes.
Wildemberg LE, Gadelha MR.
europepmc +1 more source
Current controversies in acromegaly care.
Spencer-Segal JL, Nachtigall LB.
europepmc +1 more source

